About Certara

Certara is dedicated to improving healthcare by shortening the time it takes to successfully bring a new drug to market.  We do this offering a broad spectrum of scientific consulting services and software products, with special focus on model based drug discovery and development.

Certara was formed by acquiring and integrating Tripos, Pharsight, and Simcyp, complementary companies focused on model-based approaches in different phases of  the drug discovery and development cycle, creating a company with unparalleled scientific and technical breadth from early drug discovery through Phase IV clinical trials.  Because of this, Certara is uniquely able to bring solutions forward that span the entire discovery and development cycle, eliminating traditional bottlenecks and impediments.

Quick Facts

• More than 230 employees, including 80 PhD's.
• Expertise spanning early drug discovery through Phase IV trials; uniquely able to offer end-to-end solutions that span the discovery and development cycle.
• Offices and local scientific support in North America, Europe, India and Japan.  
• Largest and most experienced team of scientific, experts dedicated to supporting strategic drug development decisions and new drug submissions, in the world.  
• Over 2,000 pharmaceutical and biotech customers and 10,000 users, from early stage discovery to late stage clinical development.
• Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) to support PK/PD Modeling and Simulation.  
• Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration’s (FDA) with the Center for Veterinary Medicine (CVM) to support PBPK modeling and simulation.  
• Certara's Simcyp Consortium is unique in the industry, a pre-competitive consortium with over 30 commercial members, and the FDA, that directs the development of the Simcyp Simulator.